# Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

> **NCT03437941** · PHASE1,PHASE2 · TERMINATED · sponsor: **Corcept Therapeutics** · enrollment: 39 (actual)

## Conditions studied

- Metastatic Castration-Resistant Prostate Cancer

## Interventions

- **DRUG:** Exicorilant
- **DRUG:** Enzalutamide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03437941
- **Lead sponsor:** Corcept Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-02-20
- **Primary completion:** 2021-10-13
- **Final completion:** 2023-01-12
- **Target enrollment:** 39 (ACTUAL)
- **Why stopped:** The level of benefit observed did not justify enrolling patients in the Dose Expansion phase of the study.
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03437941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03437941, "Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03437941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*